02 October 2023 | Monday | News
"Today marks an exciting milestone for Danaher. The successful spin-off of Veralto as an independent company creates exceptional opportunities for both Danaher and Veralto to better serve their customers, deliver on their respective strategic priorities and create greater long-term shareholder value," said Rainer M. Blair, Danaher President and Chief Executive Officer.
In connection with the separation, on September 30, 2023, Danaher stockholders received one share of common stock of Veralto for every three shares of Danaher common stock held at the close of business on September 13, 2023 (other than fractional shares, which will be aggregated and sold and the proceeds distributed to Danaher stockholders). Because the separation was completed on a Saturday and not a business day, the shares are expected to be credited to "street name" stockholders through the Depository Trust Corporation on October 2, 2023. Approximately 246 million shares of Veralto common stock were distributed in the distribution.
© 2024 Biopharma Boardroom. All Rights Reserved.